A New chapter in Deep Proteomics at HUPO 2025
At the Human Proteome Organization (HUPO) World Congress 2025, Seer, Inc. (NASDAQ: SEER) illuminated the promising realm of deep proteomics. Presented in Redwood City, California, this event showcased transformative discoveries underlining the importance of deep, unbiased proteomic insights in understanding human diseases. Seer's cutting-edge Proteograph Product Suite played a pivotal role in numerous studies, exploring various aspects of cardiovascular health, cancer, and the aging process. As researchers delve deeper, the technology shows great potential in clarifying complex biological patterns and translating those into actionable knowledge.
Seer’s Impactful Presence
Showcasing Innovations
This year's congress ensured Seer's significant technological presence, marked by over a dozen scientific presentations. Notably, the company conducted two influential talks during its exclusive breakfast symposium in addition to sixteen high-value poster presentations. These efforts collectively demonstrate the accelerating adoption of Seer's Proteograph platform across wide-ranging areas of clinical and biological research.
Quotes from Leadership
Omid Farokhzad, Chair and CEO of Seer, emphasized the significance of these advancements. “The research presented at HUPO signifies a monumental leap in scalability and relevance for proteomics,” he stated. His comments underlined the shift from specialized studies to broader population-scale discoveries. Seer, with its Proteograph platform, has become the catalyst for bridging complex molecular insights to practical clinical applications, enabling researchers to explore deeper datasets quicker and more efficiently than before.
Highlighted Scientific Presentations
Seer Breakfast Symposium
Proteomic Breakthroughs in Cardiac Dysfunction and Aging-Related Decline
Date: November 10, 2025 | Time: 8:00–9:00 a.m. ET | Location: Room Pier 2+3
Featured speakers for this engaging session included Dr. Nathan Basisty from the National Institute on Aging and Dr. Uros Kuzmanov from the University of Toronto. Dr. Basisty's findings unveil how deep proteomic analysis has helped identify indicators of physical dysfunction linked to aging. In comparison, Dr. Kuzmanov highlighted candidate biomarkers of right ventricular failure drawn from proteomic examinations of heart disease samples. Together, these presentations exemplify how Seer's technology effectively uncovers significant biomarkers that contribute to both cardiovascular and aging research.
Diverse Scientific Contributions
Over the three days of HUPO 2025, Seer’s technology was central to numerous fascinating studies:
- Scalable Plasma Proteomics Workflow Using the Seer Proteograph -- Presenter: S. Maity
- High-Throughput Plasma Proteome Profiling for Biomarker Discovery -- Presenter: S. Samra
- Exploring Complex Glycoproteomics Data -- Presenter: N. Riley
- Deep Profiling of Myocardial and Serum Samples -- Presenter: D. Davoudpour
- Plasma Profiles in Heart Failure -- Presenter: M. Di Paola
- Multi-Cancer Biomarker Discovery Enhancement -- Presenter: D. Gutierrez
- Plasma Omics Analysis in Cancer Cohort -- Presenter: S. Peterman
- Other relevant presentations emphasized diverse aspects of proteomics and potential clinical applications.
About Seer, Inc.
Seer, Inc. (NASDAQ: SEER) continues to pioneer deep proteomics, promising unprecedented insights with speed, precision, and reproducibility unmatched in the field. The Proteograph Product Suite integrates advanced engineered nanoparticles with optimized instrumentation and analytical software, effectively solving challenges that have long plagued traditional methods. The company remains committed to elevating the standards of protemics while pursuing continuous innovation in addressing research needs. It’s important to note that Seer’s products are intended for research purposes and are not designed for diagnostic use.
Frequently Asked Questions
What is Seer, Inc. known for?
Seer, Inc. specializes in deep, unbiased proteomics, providing advanced solutions for biological research.
Where was the new data presented?
The data was showcased at the Human Proteome Organization (HUPO) World Congress 2025.
Who spoke at the Seer Breakfast Symposium?
Dr. Nathan Basisty and Dr. Uros Kuzmanov presented their findings related to cardiac dysfunction and aging.
What is the Proteograph Product Suite?
It is Seer's innovative platform that streamlines and enhances the process of proteomics research.
Is Seer, Inc. involved in diagnostic procedures?
No, Seer’s products are exclusively for research use and are not intended for diagnostic applications.
